SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
215 EUR
-5.9 (-2.67%)
We assign a fundamental rating of 4 out of 10 to 56S1. 56S1 was compared to 22 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. While showing a medium growth rate, 56S1 is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
In the past year 56S1 had a positive cash flow from operations.
56S1 had positive earnings in each of the past 5 years.
In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
56S1's Return On Assets of 3.36% is in line compared to the rest of the industry. 56S1 outperforms 40.91% of its industry peers.
56S1 has a Return On Equity (6.55%) which is comparable to the rest of the industry.
The Return On Invested Capital of 56S1 (5.94%) is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for 56S1 is in line with the industry average of 9.34%.
The 3 year average ROIC (10.41%) for 56S1 is well above the current ROIC(5.94%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
56S1 has a Profit Margin (8.98%) which is in line with its industry peers.
In the last couple of years the Profit Margin of 56S1 has declined.
56S1's Operating Margin of 16.63% is fine compared to the rest of the industry. 56S1 outperforms 63.64% of its industry peers.
In the last couple of years the Operating Margin of 56S1 has declined.
With a decent Gross Margin value of 45.64%, 56S1 is doing good in the industry, outperforming 63.64% of the companies in the same industry.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 56S1 is still creating some value.
56S1 has more shares outstanding than it did 1 year ago.
The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
Compared to 1 year ago, 56S1 has an improved debt to assets ratio.
2.2 Solvency
56S1 has an Altman-Z score of 4.57. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
56S1 has a better Altman-Z score (4.57) than 77.27% of its industry peers.
The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
56S1 has a Debt to FCF ratio of 6.84. This is comparable to the rest of the industry: 56S1 outperforms 45.45% of its industry peers.
56S1 has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.50, 56S1 is in line with its industry, outperforming 59.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.57 |
ROIC/WACC0.64
WACC9.34%
2.3 Liquidity
56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
56S1 has a Current ratio of 1.05. This is in the lower half of the industry: 56S1 underperforms 63.64% of its industry peers.
A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
56S1 has a worse Quick ratio (0.50) than 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.11%, which is quite impressive.
56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 7.72%.
Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
Based on estimates for the next years, 56S1 will show a very strong growth in Earnings Per Share. The EPS will grow by 21.17% on average per year.
56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.86% yearly.
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y21.17%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 49.88, the valuation of 56S1 can be described as expensive.
Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 72.73% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Earnings ratio of 27.25, 56S1 is valued quite expensively.
A Price/Forward Earnings ratio of 40.04 indicates a quite expensive valuation of 56S1.
Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 72.73% of the companies are valued more cheaply.
56S1 is valuated expensively when we compare the Price/Forward Earnings ratio to 23.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.88 | ||
| Fwd PE | 40.04 |
4.2 Price Multiples
56S1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 77.27% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 56S1 is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.86 | ||
| EV/EBITDA | 28.7 |
4.3 Compensation for Growth
56S1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
56S1's earnings are expected to grow with 23.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.7
PEG (5Y)11.89
EPS Next 2Y23.86%
EPS Next 3Y23.06%
5. Dividend
5.1 Amount
With a yearly dividend of 0.31%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is comparable with the industry average which is at 0.54.
Compared to an average S&P500 Dividend Yield of 1.92, 56S1's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.31% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
25.37% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.37%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
FRA:56S1 (1/12/2026, 7:00:00 PM)
215
-5.9 (-2.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.88%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.93B
Revenue(TTM)2.95B
Net Income(TTM)264.50M
Analysts81.11
Price Target240.69 (11.95%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.31% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.37%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)0%
PT rev (3m)0.51%
EPS NQ rev (1m)4.24%
EPS NQ rev (3m)14.4%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)-1.45%
Revenue NY rev (3m)-1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.88 | ||
| Fwd PE | 40.04 | ||
| P/S | 7.1 | ||
| P/FCF | 55.86 | ||
| P/OCF | 28.64 | ||
| P/B | 5.18 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.7 |
EPS(TTM)4.31
EY2%
EPS(NY)5.37
Fwd EY2.5%
FCF(TTM)3.85
FCFY1.79%
OCF(TTM)7.51
OCFY3.49%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.7
PEG (5Y)11.89
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 112.98% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.75% | ||
| Profit Quality | 141.63% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.57 |
F-Score8
WACC9.34%
ROIC/WACC0.64
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y21.17%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
EBIT growth 1Y25.48%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y27.25%
FCF growth 1Y219.35%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.98%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 49.88 and the Price/Book (PB) ratio is 5.18.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.39% in the next year.